These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29623510)

  • 1. To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [
    Li L; Wei Y; Huang Y; Yu Q; Liu W; Zhao S; Zheng J; Lu H; Yu J; Yuan S
    Mol Imaging Biol; 2018 Dec; 20(6):1061-1067. PubMed ID: 29623510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
    Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
    J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy boost in patients with hypoxic lesions identified by
    Vera P; Mihailescu SD; Lequesne J; Modzelewski R; Bohn P; Hapdey S; Pépin LF; Dubray B; Chaumet-Riffaud P; Decazes P; Thureau S;
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1448-1456. PubMed ID: 30868230
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Luan X; Huang Y; Gao S; Sun X; Wang S; Ma L; Teng X; Lu H; Yu J; Yuan S
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2336-2342. PubMed ID: 27631310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
    Wei Y; Zhao W; Huang Y; Yu Q; Zhu S; Wang S; Zhao S; Hu X; Yu J; Yuan S
    PLoS One; 2016; 11(6):e0157606. PubMed ID: 27322586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
    Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
    J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
    Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
    PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
    Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
    J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
    Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
    Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pilot Study of Texture Analysis of Primary Tumor [
    Nakajo M; Jinguji M; Shinaji T; Aoki M; Tani A; Nakabeppu Y; Nakajo M; Sato M; Yoshiura T
    Mol Imaging Biol; 2019 Aug; 21(4):771-780. PubMed ID: 30397859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor angiogenesis at baseline identified by
    Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S
    J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Analysis of Dynamic
    Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
    J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.
    Koh WJ; Bergman KS; Rasey JS; Peterson LM; Evans ML; Graham MM; Grierson JR; Lindsley KL; Lewellen TK; Krohn KA
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):391-8. PubMed ID: 7673026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by
    Vera P; Thureau S; Chaumet-Riffaud P; Modzelewski R; Bohn P; Vermandel M; Hapdey S; Pallardy A; Mahé MA; Lacombe M; Boisselier P; Guillemard S; Olivier P; Beckendorf V; Salem N; Charrier N; Chajon E; Devillers A; Aide N; Danhier S; Denis F; Muratet JP; Martin E; Riedinger AB; Kolesnikov-Gauthier H; Dansin E; Massabeau C; Courbon F; Farcy Jacquet MP; Kotzki PO; Houzard C; Mornex F; Vervueren L; Paumier A; Fernandez P; Salaun M; Dubray B
    J Nucl Med; 2017 Jul; 58(7):1045-1053. PubMed ID: 28254869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
    Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
    Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.